A new cost-saving in vivo shuttle session: Syngeneic mouse tumor models

How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?

A new in vivo shuttle session will be held by end of June on a series of syngeneic tumor mouse models. These models can be run either for only efficacy monitoring or for a comprehensive assessment based on a multiparametric platform strategy for a deeper understanding of how a cancer therapy performs.

For this shuttle session, you can register and get your study scheduled in June.

A new cost-saving in vivo shuttle session: Syngeneic mouse tumor models

MCA205 sarcoma, 4T1 breast, CT26 colon, MC38 colon, EMT-6 breast, and Renca renal tumor-bearing mouse models exhibit various tumor growth profiles and differential responsiveness to PD1/PDL1 blockade. Mice were challenged with respective tumor cells and exposed to vehicle or anti-PDL1 (A) or anti-PD1 (B) antibodies. Tumor growth was then monitored overtime. (A) The three tumor models represented are differentially sensitive to PDL1 blockade - MCA205 tumors being strongly responsive while 4T1 and CT26 models are only partially responsive. (B) Differential responsiveness to PD1 blockade is also shown - while MC38 tumors are strongly sensitive to anti-PD1 antibody, EMT-6 tumors display a partial response whereas Renca model is resistant. 

Explicyte shuttle session - Take a seat


To learn more about about our multiparametric platform strategy, also have a look on our dedicated capacities!

A new cost-saving in vivo shuttle session: Syngeneic mouse tumor models

 
For more information, contact us!